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ABSTRACT
Objective To explore factors shaping the experiences of 
patients with relapsing- remitting multiple sclerosis with 
infusible disease- modifying drugs in a hospital setting.
Design and settings The critical incident technique 
served as a framework for collecting and analysing 
patients’ qualitative account practices involving infusible 
disease- modifying drugs. Data were collected through 
semistructured interviews and one single- case study. 
Participants were recruited from all five regions in 
Denmark. Inductive thematic analysis was used to identify 
and interpret factors shaping patients’ infusion journey 
over time.
Participants Twenty- two patients with relapsing- 
remitting multiple sclerosis receiving infusion with 
disease- modifying drugs (natalizumab, alemtuzumab and 
ocrelizumab).
Results Four time scenarios—preinfusion, day of 
infusion, long- term infusion and switch of infusion—
associated with the infusion of disease- modifying drugs 
were analysed to reveal how different factors could 
both positively and negatively affect patient experience. 
Time taken to make the treatment decision was affected 
by participants’ subjective perceptions of their disease 
activity; this may have set off a treatment dilemma in 
the event of a pressing need for treatment. Planning 
and routine made infusion practices manageable, but 
external and internal surroundings, including infusion room 
ambience and the quality of relationships with healthcare 
professionals and fellow patients, affected patients’ 
cognitive state and well- being irrespective of the infusion 
regimen. Switching the infusion regimen can reactivate 
worries akin to the preinfusion scenario.
Conclusion This study provides novel insight into 
the positive and negative factors that shape patients’ 
experience of infusion care practices. From a patient’s 
perspective, an infusion practice is not a solitary event 
in time but includes planning and routine which become 
an integral part of their multiple sclerosis management. 
The quality of space and the ambience of the infusion 
room, combined with the relationship with healthcare 
professionals and fellow patients, can be a significant 
source of knowledge and support people with relapsing- 
remitting multiple sclerosis in their experience of agency 
in life.
INTRODUCTION
Relapsing- remitting multiple sclerosis 
(RRMS) is an autoimmune- mediated neuro-
logical disease characterised by inflammatory 
lesion activity, axonal demyelination, and 
atrophy of the brain and spinal cord, leading 
to neurological symptoms and functional and 
cognitive impairments.1 RRMS accounts for 
up to 85% of new cases of multiple sclerosis 
(MS),2–4 with an estimated global burden of 
two to three million people.2 Expanded treat-
ment options and recognition of the need 
for more active disease control have changed 
the landscape of MS treatment.5 Disease- 
modifying drugs (DMDs) to treat RRMS 
became available in the late 20th century, 
thus creating new prospects for preventing 
neural damage and associated disabilities that 
characterise the disease.2 4 Since then, immu-
nosuppression and pulsed immune recon-
stitution therapies have expanded the DMD 
armamentarium.4 6 Treatment strategies 
have changed in line with these enhanced 
medical possibilities, with research indicating 
that early initiation of high- efficacy therapy 
is a way to obtain prolonged disease control 
Strengths and limitations of this study
 ► This is the first qualitative study exploring factors 
that influence patients’ long- term experiences of 
infusible disease- modifying drugs for relapsing- 
remitting multiple sclerosis.
 ► The critical incident technique provided us with a 
practical and time- efficient framework to explore 
patient perspectives.
 ► The study combined personal interviews with a case 
study, enabling as such the examination of phronetic 
knowledge, which is otherwise difficult to capture in 
studies based on a positivistic research paradigm.
 ► External factors could have been explored in more 
detail by using field observations.
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and stabilise or improve outcome measures of quality of 
life.5 7 8 The aforementioned conditions have increased 
the overall number of patients referred to DMD treat-
ment, including infusible administrations.9 Moreover, as 
new agents are developed, a growing number of patients 
will likely begin newly approved treatments, while others 
remain on currently available infusible therapies in the 
coming years.7 10 11 Administering infusible DMDs in a 
hospital setting requires specialist care provided by physi-
cians and nurses. To help staff navigate the different 
administration regimens, best practice guides have been 
published for alemtuzumab and natalizumab.12 13 Several 
updated guidelines have been produced for these drugs 
based on long- term postmarketing follow- up, while no 
similar recommendations are currently established for 
ocrelizumab, which was only approved by the Food and 
Drug Administration in 2017.14–16
From a patient’s perspective, receiving an infusible 
DMD (compared with injectable or oral DMDs) likely 
results in a changed relationship with healthcare profes-
sionals (HCPs) and adaption to recurring visits to receive 
scheduled infusions. Although treatment by infusion is 
a common hospital practice, there seem to be very few 
published studies exploring patients’ perspectives once 
treatment is commenced.17 Foley and Dunne18 discussed 
management and operational settings, including a section 
on staffing and costs, in addition to mentioning patient 
preferences concerning in- office facilities, arguing this 
to be a more ‘comfortable and familiar’ setting. Ostrov17 
and colleagues reported on patient preferences and satis-
faction with an infusion centre, but only to quantify if 
patients preferred receiving their infusion in specialty or 
multispecialty care. In a report by Baker19 and colleagues 
on the relocation of rheumatology patients receiving a 
similar disease- modifying infusion, a detailed descrip-
tion was provided of the organisational challenges associ-
ated with moving, rearranging equipment, staff training 
and reimbursements. Although relocation was in part 
augmented by patients’ discomfort of receiving treatment 
in an oncology setting, patients’ experiences or satisfac-
tion with the new infusion location were not mentioned 
in the conclusion of the report. Assessing patients’ 
perspectives and values can help to build a holistic infu-
sion practice, and as current research literature is limited 
in voicing patients’ experience specifically in infusion 
practices, this calls for a study on how patients experi-
ence their ‘infusion- journey’, from the novel beginning 
to the ‘long- term’ treatment trajectory, as well as the 
impact of such treatments on everyday life. As a guide for 
patient- focused infusion practices, the present study aims 
to explore factors influencing patients’ experiences of 
receiving infusible DMD treatments for RRMS.
METHODS
Study design and data collection
To explore qualitative experiences within an organi-
sational setting, the critical incident technique (CIT) 
(box 1) was chosen as a functional framework to explore 
contextual factors such as experiences, activities, values 
and behavioural activities.20 21
The CIT originated from Flanagan22, who performed 
psychological studies of aviation personnel during World 
War II in an effort to develop a rapid qualitative analysis of 
air fighters’ actions and reactions during different combat 
conditions in the cockpit. The CIT is now recognised as a 
focused and time- efficient method and has proven highly 
practical to collect and analyse human experiences in 
various professional contexts and to address problems 
in the cross- field between human actions and health 
organisations.23–28
In the present study, an ‘incident’ was broadly defined 
as any experiences, behaviours, thoughts or feelings 
related to a patient’s infusion therapy, including the time 
before the infusion day, during the infusion day, time 
after and between infusion days, and in between clin-
ical monitoring (ie, blood monitoring). Semistructured 
interviews supplemented by a single- case study served as 
complementary data collection methods from which inci-
dents were later extracted. The Consolidated criteria for 
reporting qualitative research list for qualitative studies 
was used in drafting the present manuscript.29
Recruitment and settings
Participants were recruited between February and August 
2019 from five main regions in Denmark. A written invi-
tation stating the study’s purpose and assuring confiden-
tiality and anonymity and researchers’ background were 
broadly explained in a leaflet. A snowball effect was used 
by distributing the leaflet through social media, circulated 
by participating neurologists, and through the Danish 
Multiple Sclerosis Society web page. More information 
could be obtained by contacting the study manager. 
Eligibility criteria were RRMS and receiving intravenous 
treatment with DMD, minimum age of 18 years, and able 
to provide informed consent on his/her behalf. Patients 
with primary progressive and secondary progressive scle-
rosis were excluded. If a patient was eligible and willing to 
participate, a detailed letter and informed consent form 
were forwarded. Final inclusion was at the discretion of 
the patient. If choosing to participate formally, a meeting 
was scheduled and interview questions emailed in prepa-
ration for the forthcoming interview. Interview settings 
(face- to- face or Skype) was at the discretion of the partic-
ipants. Attending an interview was further reassured with 
Box 1 Analysis stages of the critical incident technique
Determining the aim of the activity.
Setting the plans, specifications and criteria.
 ► The observer(s).
 ► The observations.
 ► Behaviours or experiences.
 ► Collecting the data.
 ► Analysing the data.
 ► Reporting the findings.
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confidentiality and anonymity before final inclusion into 
the study. No correlation measures were planned for this 
qualitative study; thus, no hospital records on disability 
status or other clinical characteristics were collected.30
Interviews
Individual semistructured interviews were conducted 
with patients with RRMS who were being treated with 
an infusible DMD. Irrespective of the product brand 
the interviews sought unifying experiences which could 
explore beyond preference treatment frequency and 
provide insights about meaningful conditions to consider 
in practical MS management. The interview was governed 
by seven interview questions exploring situations and 
experiences, which could prompt further descriptions of 
key areas along the infusion journey (box 2) and lasted 
between 31 and 75 min.
The interview questions were emailed to all participants 
before the interview to prompt reflections and served as 
a semistructured guide. Each interview was preceded by 
the collection of demographic and treatment data. The 
participants were motivated to start their story from the 
time when infusible treatment was brought up by the 
neurologist. Probing questions, such as ‘how do you feel 
about this’ or ‘please, tell me more about this’, were used 
and encouraged participants to provide rich details. All 
interviews were concluded by asking the participants 
if any other issues were missing from the conversation. 
The interviews were recorded and conducted by the 
first author, who was a trained qualitative interviewer, 
and all transcripts were returned to the participants for 
comments. The interviews lasted between 30 and 80 min 
and were transcribed verbatim by an external profes-
sional transcriber.
Single-case study
A single- case study was chosen to supplement interviews 
and provide an indepth perspective of a typical first- time 
DMD infusion.31 Case studies are characteristic methods 
to explore practical virtues (phronetic knowledge), 
which are otherwise problematic to capture in large- scale 
cohorts.32 Different types of case studies can apply and 
serve as complementary data collection for a larger set 
of interview data.33 In this study, the motivating assump-
tion to choose a representative case was that a patient, 
unfamiliar with the DMD infusion procedure, would 
have unique proximity to the events and procedures 
surrounding infusion practices and provide insights 
which could be difficult to collect in patients who had 
become more familiar to their treatment procedures. 
The case selection was thus based on a request to include 
a patient who was naive to treatment with DMD and infu-
sion procedures. This way a ‘first- hand’ impression could 
be explored as it were forming. The inclusion criteria 
for the case study were then a patient who could repre-
sent a typical patient with RRMS, female, aged between 
20 and 50 years, and newly diagnosed.2 Field notes and 
interviews, including peers on three of the four observa-
tions, formed the data set. An overview of the case study is 
presented in table 1.
Data analysis
Given the paucity of previous studies on this particular 
subject, an inductive thematic analysis approach was 
considered appropriate, including criteria for good 
thematic analysis.34 Data were structured using the NVivo 
V.12 Pro software. The analysis started by revisiting the 
interviews by first listening to the sound recordings and 
reading the transcripts several times, to obtain an overall 
impression of each patient’s infusion journey. To struc-
ture the analysis, the time scenarios—preinfusion, first day 
of infusion, long- term infusion and switch of infusion—were 
chosen to frame the progressing analysis. Following the 
CIT requirements, incidents which either affected the 
infusion experience or had a more subtle connection to 
the infusion were explored. Using the NVivo software, 
transcriptions were imported and a detailed approach 
was undertaken to arrange and rearrange the text data 
into each of the high- level time scenarios. Supported by 
the written field notes from the case study and interviews, 
initial notes on emerging themes were added into the 
software program. All transcripts were searched through 
and relevant incidents captured into the different time 
scenarios, a line- by- line approach completed the analysis, 
and positive and/or negative experiences were explored 
for each domain. Interviewer expectations and possible 
prejudice were dealt with by adopting a reflective stance 
towards emerging themes. Furthermore, the research 
team, consisting of a trained qualitative researcher and 
three neurologists involved in MS research and with expe-
riences in patient- centred research projects, reflected and 
discussed emergent themes during the NVivo analysis 
and writing of the results. This systematically paved the 
Box 2 Reflective semistructured interview guide
Background
 ► Age and years with relapsing- remitting multiple sclerosis.
 ► Years on current infusible treatment.
Reflections of infusion treatment experiences
 ► How do you experience your life with infusion treatment (past, pres-
ent, future)?
 ► Please tell me about how the infusion began.
 ► Please describe how a normal day looks like when you are going to 
infusion treatment.
 ► Please describe an event, in relation to infusion treatment, which 
has affected you positively.
 ► Please describe an event, related to infusion treatment, which has 
had a negative effect on you.
 ► Please describe what makes it difficult going to/or receiving infusion 
treatment.
 ► What makes it easier?
 ► What affects your situation (both positive/negative) re-
lated to monitoring and follow- up on infusion treatment? 
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way for a reflective and rigorous presentation of possible 
infusible DMD experiences. Quotations are in this article 
chosen to provide a possible human experiential account 
of the themes and should thus not be correlated to other 
labels such as gender, age or disease duration.
Patient and public involvement
There was no time or resources allocated to include 
patient and public involvement (PPI) in this study. 
Patients and the public will be invited to discuss and 
refine the usability of the results.
RESULTS
Twenty- eight patients responded to the study invitation 
from either the social media ad or the flyer present at 
the MS clinics. Twenty- five were considered eligible for 
inclusion and 22 responded to follow- up scheduling. 
Twenty- one participated in the interviews and one female 
patient was approached to represent the single- case study, 
which she acknowledged. Patient demographics and 
summary of infusion treatment are shown in table 2.
Incidents were arranged into the four time scenarios, 
and nine subthemes were found to be factors affecting 
participants’ infusion journey (table 3).
Preinfusion initiation
The decision
A clear factor promoting the decision to proceed with 
infusible treatment was connected to a personal percep-
tion of participants’ own physical functioning, with 
decisions reached more rapidly if the physical decline 
was ongoing: “I had this period with all those attacks. 
So, I had these physical situations which prompted me 
to (swear word)…whatever they would give me I would 
have accepted.” Another participant described infusion 
treatment as an opportunity to get better when her body 
had become unmanageable, saying “It was a lifeline. I just 
wanted to be (bodily) at peace.” Conversely, if an infusion 
treatment was suggested by the neurologist but a decline 
in functioning was not felt explicitly, they took their time 
to weigh up the consequences. In the case of patients 
being newly diagnosed and suffering from debilitating 
attacks, the seriousness of the situation made it particu-
larly clear that radical action was needed. In participants 
who had previously experienced daily side effects from 
oral or injectable DMDs, the prospect of an infusion treat-
ment was considered as a ‘relieve’. One participant said: 
“The shift to infusion was nice. My body was quite worn 
out after having to inject myself for so many years.”
Treatment dilemma
A delaying factor in the decision phase was caused by the 
inherent dilemma of having to decide on a treatment for 
which the clinical response and long- term outcomes were 
ultimately unknown. Further discussions about treat-
ment were dealt with within the family and additional 
information was actively pursued via online social media. 
Discussions with peers made the preinfusion time more 
bearable. Moreover, confidence in the neurologist helped 
to make the decision- making process smoother. From 
the case study, we learnt that continuity of a designated 
neurologist and the department’s efforts to coordinate 
Table 1 Case study overview
Case study Baseline Follow- up 1 Follow- up 2 Follow- up 3
Time June June July August
Infusible Disease- modifying 
drug
First course Blood monitoring Second course Third course
Interviews at the hospital site, 
after infusion treatment
37 min (parent 
included)
– 20 min (partner 
included)
27 min (partner 
included)
Home interview – 23 min (no peers included) – –
Field notes ✓ ✓ ✓ ✓
Transcript summary ✓ ✓ ✓ ✓
Table 2 Patient demographics and summary of infusion 
treatment
(N=22)
Gender (female/male) 17/5
Age (years)
  Mean 40.18
  Median 41.5
  Range 25–54
Disease duration (years)
  Mean 9.4
  Median 9.5
  Range 1 month–23 years
Infusion duration (years)
  Mean 2.49 years (29.90 months)
  Median 8.5
  Range 1 week–12 years
Infusion treatment
  Natalizumab 13
  Ocrelizumab 5
  Alemtuzumab 4
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necessary diagnostic examinations kept waiting times to 
a minimum. The case participant and family said: “you 
are not just a number.” Regardless of any hesitation about 
proceeding with infusion treatment, participants summed 
up the situation as a proactive decision to control their 
disease. The dilemma was resolved for some by choosing 
what they considered best for the time being. A partic-
ipant said: “It sounds dramatic, but I have made peace 
with it” (infusion treatment).
First day of infusion
Framing the day
Participants were often met by a designated infusion 
room nurse who explained the procedures that were 
to be followed. Providing patients with a schedule and 
showing them the departmental facilities helped to frame 
an otherwise tense day and create a safe and comfortable 
atmosphere. For some participants, pretreatment descrip-
tions of the forthcoming infusion had sounded harsh, and 
in retrospect they felt that they had worried excessively. 
However, the inherent uncertainty of the whole situation 
lent room for much concern, even more so in the case of 
participants who were newly diagnosed: “To sit there…
as recently diagnosed and with all bodily functions over-
turned. That was actually pretty stressful.” As a control for 
possible side effects, some patients were asked to return 
to the infusion centre for a check- up a few days after 
treatment initiation. This initiative made participants feel 
safe while still being in a vulnerable situation. Starting on 
infusion was also perceived as providing valuable access 
to specialist care: “It was a relief for me to come in (to the 
hospital) and receive the infusion because I gained access 
to something which provided me with security.”
Support and external conditions
Participants were often in the company of a relative on 
the first days of infusion and were afraid of not capturing 
important messages from healthcare staff: “I had my 
husband with me. I needed the extra ears. I think he 
needs to hear about the treatment as well.” Addition-
ally, the shared experience of being together with family 
members made it easier afterward to talk about proce-
dures and communication with staff. The informal talk 
between the regular patients and the staff in the infusion 
room could cross personal boundaries for newly diag-
nosed participants: “At the beginning, I couldn’t take in 
what the others were talking about. I think I will bring my 
headphones next time. There was a conversation going 
on in the room, which you wouldn’t normally be a part 
of.” Practical conditions like finding a parking spot or 
directions to department or laboratory were factors that 
complicated the initial infusions and often mentioned as 
stressful.
Long-term infusion
Planning and routine
Participants described how quickly they got into the 
routine of going to the hospital for infusions. Having a 
routine, before and after infusion visits, was a factor that 
made the different procedures workable. Experienced 
to the infusion practices a participant said: “It follows a 
straight line. I know what to do, where to go, and where to 
sit. It’s like when I need my morning routines; otherwise, 
I get confused and stressed. It’s nice to have the routines.” 
Having a frame in place added to cognitive stability. More-
over, routines were an important way to control stress 
and fatigue and additionally served to release energy 
for other life priorities. Factors hampering participants’ 
routines could, for example, be a forthcoming relocation 
of the infusion centre. In such cases, participants worried 
about transportation and how it might affect their job 
situation: “It stresses me physically to move location and 
not knowing where to park and if there will be available 
spaces.” Overall, the hassle of finding a free parking space 
was mentioned as a major contributor to stress and poor 
cognitive functioning.
The infusion room
External surroundings and conditions were mentioned 
as stressful, for example, if chairs were broken and the 
room temporarily placed, for example, in a busy corridor 
or not shielded from other hospital activities. Although 
recognising the staff’s effort to make it as comfortable as 
possible, these circumstances made infusion treatment a 
strenuous affair and left participants feeling stressed and 
unprioritised. The atmosphere of the room also formed 
part of the overall experience, both positive and nega-
tive. One participant bluntly said: “We all know that it’s a 
(swear word) situation, but the atmosphere (in the infu-
sion room) doesn’t have to be.” A ‘good infusion day’ was 
a balance between being able to relax while also having 
light and humorous conversations: “We have a lot of fun. 
I don’t feel like it’s a hospital. I feel at home.” Conversely, 
participants described how loud noises, overcrowding 
or just the tone in the room from fellow patients or staff 
affected their experience and contributed to stress and 
fatigue for the remainder of the day.
Relationships and knowledge
Relationships between fellow patients developed over 
time, and participants described how being in the 
Table 3 Time scenarios and themes
Preinfusion initiation  ► The decision.
 ► Treatment dilemma.
First day of infusion  ► Framing the day.
 ► Support and external 
conditions.
Long- term infusion  ► Planning and routine.
 ► The infusion room.
 ► Relationships and knowledge.
 ► A ‘breathing’ space.
Switching infusion  ► Reappearing worries.
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infusion room became a source of continuous education 
about MS management as well as a connection to new 
research knowledge about MS. The informal exchange 
of knowledge, especially from the nurses, was some-
thing the participants valued, making them feel part of a 
community and giving them hope for the future. Access 
to staff during or between the infusions provided partic-
ipants with opportunities to ask questions and to receive 
more direct answers and feedback from a nurse or doctor 
compared with when they had to call the department 
during specific phone- in hours.
A ‘breathing space’
Overall, participants seemed to associate infusion treat-
ment by taking matters into their own hands and actively 
doing something to prevent MS worsening. While some 
participants had considered their self- administered treat-
ment (orals or injections) at home to be convenient, a 
paradoxical aspect of spending time at the hospital meant 
that participants could put thoughts of MS aside: “It was 
an annoyance to have to remember this (the pills) all the 
time. You can let go of that. I could put MS aside.” Related 
to this experience, an infusion at the hospital could also 
be associated with a positive break from everyday issues. 
“It ended up being a space I could breathe. I had small 
kids at home, so I found a space where I could relax and 
just be me without having to fix things or take care of a 
child.” Once the worries of starting an infusion treatment 
had been reconciled, an infusion day could thus be a valu-
able time out or even a space to recharge from a busy life.
Switching infusion
Reappearing worries
A few of the participants had switched from one infus-
ible DMD to another due to side effects with the former. 
Changing infusion intervals meant changing routines, 
and in most cases this was unproblematic. However, 
if communication about future treatment options 
concerning current side effects was not talked through 
with a neurologist, this could create significant new fear 
and worries resembling the pretreatment time point.
DISCUSSION
This study explored factors shaping patients’ experi-
ences of receiving an infusible DMD for RRMS. Following 
four phases of the infusion journey, from preinfusion, 
first day, long- term treatment and switching to other 
DMD infusions, we found several different contextual 
factors affecting both positive and negative experiences 
during each time phase.
Physical function, present disease activity and medical 
uncertainty about treatment outcomes were factors 
that influenced time before the final decision and 
prompted a treatment dilemma. Likewise, in a study 
by Lee Mortensen and Rasmussen,35 which explored 
preferences of patients with MS related to the quality 
of life, it was found that the perception of present 
health subsequently impacted on choice and commit-
ment to treatment. Our study raises the question of 
whether dissimilarities between clinical measures and 
patients’ subjective symptoms might stall treatment 
initiation, making it even more important that patients 
understand that treatment delays can lead to a poorer 
long- term outcome.1 Peer involvement, and trust and 
involvement from the neurologists and nurses were 
recognised as positive factors that supported partic-
ipants’ proactivity and autonomy. Coming to a firm 
conviction about treatment choice formed part of the 
process each patient went through when getting ready 
to incorporate a new treatment procedure in their life. 
In a qualitative study of patients with RRMS receiving 
a monthly infusion, Miller et al36 concluded that fear 
and uncertainty were unavoidable factors suffered by 
persons with MS. They furthermore touched on the 
dilemma of treatment choice, summing up that patients 
valued ‘quality over quantity’ when deciding on a high- 
risk treatment. Choosing infusion treatments for RRMS 
can be viewed as a complex medical decision since a 
cure is not guaranteed and the potential benefit has 
to be weighed up towards possible side effects.37 38 Our 
study extends these assumptions by empirically demon-
strating that HCP and active family involvement in a 
treatment dilemma support patients’ proactivity and 
lay the foundation for assuredness with the treatment 
decision and making personal peace with the situation. 
Further investigation is required to determine if talking 
about the dilemma inherently embedded in a complex 
MS treatment landscape and options could actually 
help to provide an optimal decision- making process.
By contextualising the first day of infusion, staff 
created a safe and comfortable environment for partici-
pants new to infusion treatment. While some associated 
the new infusion option as a way to gain the security 
of more regular medical monitoring and were happy 
with hospital visits, others had an overstated fear of the 
infusion procedure, contributing to overall worries and 
uncertainty about the day. Peer support continued to 
be a positive factor during infusion initiation, although 
less support was needed as patients became more confi-
dent with the infusion procedures. External factors 
such as easiness of parking or poor signage on the 
hospital grounds continued to hamper the overall expe-
rience. Moreover, the interior of the infusion room, for 
example, functionality of chairs and infusion location, 
also impacted participants’ experiences. If an infusion 
room was placed far from the nurses’ station or not 
shielded from other activities, hospital visits became 
stressful and fatigue was heightened. The atmosphere 
in the infusion room could also facilitate both positive 
and negative experiences; an optimistic and humorous 
tone from staff and fellow patients was valued as positive 
when balanced between seriousness and light- hearted 
ambience. In contrast, overcrowding or a loud nega-
tive tone in the room prompted participants to seclude 
themselves and avoid conversation.
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Relationships with staff and fellow patients were an 
important positive factor in keeping participants up 
to date with new knowledge and research about MS. 
Moreover, during infusion hours or informal check- ups, 
participants felt a strong, easy and direct line of 
personal communication with hospital staff. Infusion 
hours provided some participants with much- needed 
sanctuary, ultimately allowing participants time to focus 
on life away from their illness.
Edvardsson and colleagues39 found that an atmo-
sphere of ease was shaped by how patients perceived the 
hospital environment, including being located in safe 
and familiar surroundings, being recognised by staff, 
and benefiting from communication with others. More-
over, natural light and the aesthetics of a hospital room 
were considered a strong accompaniment to overall 
well- being.40 Studies examining how hospital environ-
ment, ambience, relationships and communication 
affect patients’ well- being and recovery are not new, 
although it could be argued that hospital constructions 
and interior design only recently have begun to practi-
cally include knowledge of how hospital environment 
affects health. Our study contributes to this body of 
knowledge and extends it in the sense that the hospital 
environment, even in infusion rooms with short- term 
visits, significantly affects patients’ cognitive state and 
overall well- being. While this study touches only briefly 
on external factors such as parking and signage, HCPs 
can relatively easily consider aspects of the interior 
of the infusion room, including ambience, lighting, 
equipment location and seating arrangements. Further 
research should focus on the external environment and 
how physical and mental perceptions of an infusion 
room might support the cognitive function and well- 
being of patients receiving infusions.
Within healthcare delivery services, including biolog-
ically infused treatments for RRMS, there is a trend 
towards moving complex medical treatments from 
the hospital environment to a homecare scenario.41 
While this may be a positive development for some 
patient groups, our study shows that hospital- based 
infusion treatment provides patients with significant 
security, knowledge and support in dealing with their 
MS and would be problematic if lost. A recent study 
on new models of care for the home- based infusion of 
DMDs serves as an example of this.42 According to the 
report, patients were opposed to giving up relation-
ships with departmental staff, and researchers had to 
promise the participants that they could return to usual 
hospital procedures after completion of the study. This 
stresses the need to explore patient perspectives before 
attempting to introduce new healthcare practices and 
organisations.
A few participants in this study had recently switched 
from one infusible DMD to another, which in some 
cases reactivated a similar experience of uncertainty as 
seen in treatment- naive patients during preinfusion. 
Besides these worries, participants spoke about their 
concerns related to changing treatment, for example, 
from infusion to oral treatment, even when this issue 
had not been raised by a neurologist. Future research 
could benefit from looking further into how patients 
can be supported during a treatment switch.
Limitations
The voluntary nature of the recruitment might have 
motivated people with a positive outlook of infusions to 
participate. However, the participants raised both positive 
and negative incidents regardless and seemed motivated 
by a genuine wish to speak about their infusion journey. 
Considering the qualitative study design used here, our 
sample size of 22 was a balance between extraction of 
enough incidents and appropriate to perform a thor-
ough qualitative analysis,33 43 although repeated inter-
views with fewer participants could have provided more 
detailed narratives, particularly in consideration of 
possible recall biases. However, using a case study here 
strengthened the analysis concerning the initial infusion 
phase and provided a unique insight into how infusion 
treatment is experienced from the perspective of a newly 
diagnosed patient. The integrity of the results was further 
enhanced by the inclusion of a diverse patient popula-
tion from three different infusible DMD regimens, which 
made it possible to collect unifying experiences across the 
different frequencies of treatment regimens. Some partic-
ipants had understood the interview questions relating to 
procedural or medication errors. This was dealt with by 
repeating the research objectives before the interview 
and emphasising that compiling details of medication 
errors was not the aim of the study. A limitation of the 
study design was that no peers were included for the indi-
vidual interviews. Undertaking a family perspective might 
enhance understanding of the context of treatment 
dilemmas and treatment switches with infusible DMDs.
CONCLUSION
This study explored factors influencing patients’ experi-
ences with infusible DMD treatment for RRMS beyond 
individual preferences and reports on meaningful 
unifying conditions which can serve as a guiding point 
in MS infusion management in practice. Starting on an 
infusible DMD is a treatment dilemma involving both 
HCPs and families of patients with MS. Active MS with 
declining physical function seems to shorten patients’ 
preinfusion decision phase, while dissimilarities between 
bioclinical markers and patients’ subjective disease expe-
rience might prolong it. Patients with RRMS habituate 
treatment procedures with infusible DMDs into their 
daily lives regardless of treatment frequency. External 
and internal hospital surroundings, including infusion 
room ambience, affect patients’ cognitive state and well- 
being. Positive relationships with staff and fellow patients 
transform the infusion experience to a time character-
ised by personal support, continuous learning and an 
opportunity for a positive ‘time out’ allowing patients to 
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redirect focus to other aspects of their lives. Peer relation-
ships are vital in MS management and future research 
could benefit from including the role of peers, especially 
during treatment start of a new infusible and switch to 
other infusible treatments.
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